Lisa M. Landrum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lisa M. Landrum has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Joan L. Walker
Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
6 shared publicationsD. Scott McMeekin
Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
5 shared publicationsKathleen N. Moore
University of Oklahoma Health Sciences Center, 800 NE 10th St., Oklahoma City, OK, 73014, USA
5 shared publicationsGrainger S. Lanneau
Naval Medical Center San Diego, San Diego, CA, USA
3 shared publicationsMichael A. Gold
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
3 shared publicationsNatalie Gould
2 shared publications
Latest Publications
- 6 July 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (3) , 562-569
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
- 6 July 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (3) , 562-569
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 459-467
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
- 1 March 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 144 (3) , 459-467
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 204-209
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 204-209
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study
- 1 May 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 137 (2) , 193-202
Comprehensive care in gynecologic oncology: The importance of palliative care
- 1 May 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 137 (2) , 193-202
Comprehensive care in gynecologic oncology: The importance of palliative care
- 1 January 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 132 (1) , 50-54
Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
- 1 January 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 132 (1) , 50-54
Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
- 1 July 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 130 (1) , 12-18
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study
- 1 July 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 130 (1) , 12-18
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study
- 30 September 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 122 (3) , 527-531
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
- 30 September 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 122 (3) , 527-531
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
- 1 February 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (2) , 337-341
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
- 1 February 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (2) , 337-341
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
- 1 March 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 108 (3) , 584-590
Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
- 1 March 2008
- Published by Elsevier in Gynecologic Oncology
- Vol. 108 (3) , 584-590
Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
- 1 February 2008
- Vol. 101 (2) , 38-9
Uterine leiomyoma with associated pseudo-Meigs syndrome mimicking ovarian carcinoma.
Uterine leiomyoma are commonly diagnosed in women of reproductive age. However, these benign tumors may present with clinical signs and symptoms that are consistent with ovarian carcinoma. A 47-year-old gravida 0 presented with a large pelvic mass, ascites, bilateral pleural effusions, and an elevated CA 125 worrisome for ovarian carcinoma. Exploratory laparotomy revealed a 20,120 g pelvic mass, with 2 L ascites, and pelvic and periaortic lymphadenopathy. Final pathology was consistent with a benign giant leiomyoma. Postoperative course was complicated by reaccumulation of pleural effusion requiring therapeutic thoracentesis and diuretics. Patient had return to full activity with 50 pound weight loss at 8 weeks after surgery. Elevated CA 125 levels and ascites are often associated with ovarian carcinoma, but it is also important to keep benign processes in the differential diagnosis when considering malignancy.
- 1 February 2008
- Vol. 101 (2) , 38-9
Uterine leiomyoma with associated pseudo-Meigs syndrome mimicking ovarian carcinoma.
Uterine leiomyoma are commonly diagnosed in women of reproductive age. However, these benign tumors may present with clinical signs and symptoms that are consistent with ovarian carcinoma. A 47-year-old gravida 0 presented with a large pelvic mass, ascites, bilateral pleural effusions, and an elevated CA 125 worrisome for ovarian carcinoma. Exploratory laparotomy revealed a 20,120 g pelvic mass, with 2 L ascites, and pelvic and periaortic lymphadenopathy. Final pathology was consistent with a benign giant leiomyoma. Postoperative course was complicated by reaccumulation of pleural effusion requiring therapeutic thoracentesis and diuretics. Patient had return to full activity with 50 pound weight loss at 8 weeks after surgery. Elevated CA 125 levels and ascites are often associated with ovarian carcinoma, but it is also important to keep benign processes in the differential diagnosis when considering malignancy.